Coronary computed tomography angiography and $[^{15}\text{O}]\text{H}_2\text{O}$ positron emission tomography perfusion imaging for the assessment of coronary artery disease

P. A. van Diemen · S. P. Schumacher · R. S. Driessen · M. J. Bom · W. J. Stuijfzand · H. Everaars · R. W. de Winter · P. G. Raijmakers · A. C. van Rossum · A. Hirsch · I. Danad · P. Knaapen

© The Author(s) 2020

Abstract  Determining the anatomic severity and extent of coronary artery disease (CAD) by means of coronary computed tomography angiography (CCTA) and its effect on perfusion using myocardial perfusion imaging (MPI) form the pillars of the non-invasive imaging assessment of CAD. This review will 1) focus on CCTA and $[^{15}\text{O}]\text{H}_2\text{O}$ positron emission tomography MPI as stand-alone imaging modalities and their combined use for detecting CAD, 2) highlight some of the lessons learned from the PACIFIC trial (Comparison of Coronary CT Angiography, SPECT, PET, and Hybrid Imaging for Diagnosis of Ischemic Heart Disease Determined by Fractional Flow Reserve (FFR) (NCT01521468)), and 3) discuss the use of $[^{15}\text{O}]\text{H}_2\text{O}$ PET MPI in the clinical work-up of patients with a chronic coronary total occlusion (CTO).

Keywords  Coronary computed tomography angiography · Positron emission tomography · Myocardial perfusion imaging · Hybrid imaging · Coronary artery disease · Chronic coronary total occlusion

Introduction  Coronary atherosclerosis is marked by a chronic inflammation of the coronary arteries leading to accumulation of lipids and inflammatory cells in the arterial wall (plaques) [1]. Development of plaques may take decades but by diminishing blood flow to the subtended myocardium can eventually lead to ischaemia causing symptoms such as chest pain and dyspnoea. It is vital to assess the presence and extent of coronary artery disease (CAD) in patients with suspected CAD in order to determine the correct diagnosis and appropriate treatment strategy [2]. The non-invasive imaging modalities, coronary computed tomography angiography (CCTA) and positron emission tomography (PET) myocardial perfusion imaging (MPI) are widely utilised to that extent and assess the anatomic severity and functional significance of CAD, respectively. In this review we will highlight the assessment of CAD by means of CCTA and $[^{15}\text{O}]\text{H}_2\text{O}$ PET MPI focussing on studies performed by Dutch investigators.

Coronary computed tomography angiography  CCTA may represent a good alternative for invasive coronary angiography (ICA), especially in patients with a low or intermediate pre-test likelihood of CAD [2]. It is an anatomical imaging modality that allows for the assessment of extent and severity of coronary atherosclerosis. A large body of evidence demonstrates that CCTA is able to exclude significant CAD with a near to absolute certainty due to its excellent sensitivity and negative predictive value [3]. Nevertheless, it is hampered by a high rate of false-positive findings and as such its specificity and positive predictive value is only moderate [3]. This is explained by the tendency of CCTA to overestimate the severity
of disease due to artifacts caused by, for example, calci-
cifications, known as ‘blooming artifacts’ (Fig. 1; [4]).
Prospective studies have shown that patients who
underwent CCTA as a first-line test were more likely
to be referred for ICA and even be revascularised as
a consequence compared with those who underwent
a functional test or standard care [5, 6]. On the other
hand, the rate of non-obstructive CAD on ICA follow-
ing CCTA is also higher as compared with a diagnostic
strategy that utilises a functional test [5]. This high-
lights the limitations of CCTA since the burden of
calcification seen on computed tomography does not
directly relate to the degree of luminal obstruction,
let alone its functional consequences. However, CCTA
has justly acquired a prominent place in contempo-
rary guidelines as a first-line test for the evaluation
of symptomatic patients with a low to intermediate
pre-test likelihood of obstructive CAD [2]. Accord-
gingly, guidelines recommend a functional test in the
presence of obstructive CAD on CCTA, known as the
hybrid approach, as viable diagnostic strategy in order
to minimise the rate of false-positive CCTA findings
and as such lead to a more judicious referral for
ICA [2]. Recently, a CCTA-based technique has been
developed that assesses lesion-specific ischaemia,
namely FFRct: fractional flow reserve derived from
CCTA [7]. FFRct (HeartFlow Inc. Redwood City, USA)
uses computational fluid dynamics and a 3D model of
the coronary vasculature derived from standard CCTA
datasets to calculate FFR [7]. Prospective trials have
consistently demonstrated FFRct to accurately detect
lesion-specific ischaemia [3, 8, 9]. The FFRct PACIFIC
sub-study was the first study to compare the accuracy
of CCTA, FFRct, single-photon emission computed
tomography (SPECT), and positron emission tomog-
raphy (PET) myocardial perfusion imaging (MPI) in
a head-to-head manner and demonstrated FFRct to
exhibit the highest accuracy for lesion-specific is-
chaemia as referred by invasive FFR. Noteworthy,
FFRct could not be obtained in 17% of the vessels
[10]. Furthermore, incorporating FFRct in CCTA as-
essment possibly reduces healthcare costs without
a penalty to clinical outcome as compared with stan-
dard care [11]. Fig. 1 demonstrates how FFRct can
lead to a more prudent referral pattern for ICA. An-
other approach to predict the functional significance
of CAD solely based on CCTA is related to para-
ters of severity and burden of atherosclerosis, such
as total plaque volume, non-calcified plaque volume
and adverse plaque characteristics that have all been
linked to the presence of ischaemia [12–14]. These
analyses are, however, time-consuming and therefore
not yet applicable in daily practice. Implementation
of new technologies such as machine learning may
overcome this barrier [15]. Machine learning has the
potential to run these analyses swiftly and with high
accuracy and consistency. Future studies, such as the
CONFIRM-II trial, will investigate whether machine-
learning analysis provides improved diagnostic ac-
curacy and prognostication compared with human
readers.

**[[15O]H2O PET perfusion imaging**

Nuclear-based functional testing is at the heart of
diagnosing CAD. For decades, the field of MPI has
been dominated by SPECT. From the outset, SPECT
has been the MPI workhorse. However, over the last
years a switch from SPECT to PET MPI has been
taking place, given the increasing availability of PET
scanners and 82Sr/82Rb generators, lower radiation ex-
posure, improved resolution, ability of PET to quantify
perfusion in absolute terms (in ml/min/g) and lastly
superior pharmacokinetics of the tracers used as
compared with SPECT tracers [16]. There is a wide
variety of PET perfusion tracers available such as
82Rb, 13NH3 and [15O]H2O [16, 17]. Nowadays, 82Rb
is the most widely utilised tracer; however, clinical
use of [15O]H2O is expected to take a leap forward
with the completion of a multicentre phase III trial
that will evaluate [15O]H2O PET versus ICA and cur-
cent best practice SPECT imaging to obtain United
States of America (USA) Food and Drug Administra-
tion (FDA) approval for [15O]H2O as a PET tracer in
the USA. There are some distinct pharmacokinetic dif-
cferences between the tracers. Both 82Rb and 13NH3
are transported to and trapped within the myocardium,
whereas [15O]H2O is freely diffusible, metabolically
inert and completely extracted from the arterial blood
pool by myocardium rendering it an ideal tracer to
quantify myocardial blood flow (MBF) in ml/min/g
(Fig. 2; [16, 17]). The added value of MBF quantifi-
cation is that it allows for detection of microvascular
disease and three-vessel disease or left main disease.

**Dutch contribution to the field**

- The Amsterdam UMC, Vrije Universiteit Amster-
dam, is one of the few sites worldwide that uses
[15O]H2O PET MPI for the assessment of CAD.
- The PACIFIC trial conducted by the Amsterdam
UMC, Vrije Universiteit Amsterdam was the first
study to compare the diagnostic performance of
CCTA, SPECT, [15O]H2O PET and hybrid imaging
in a true head-to-head fashion using FFR as ref-
ence standard.
- Numerous PACIFIC trial substudies have con-
tributed to an improved understanding of the
assessment of CAD by means of CCTA and
[15O]H2O PET.
- In the dedicated CTO program of the Amsterdam
UMC, Vrije Universiteit Amsterdam, [15O]H2O
PET MPI has been employed to assess the pres-
ence of ischaemia in patients with a possible
indication for percutaneous revascularisation of
their CTO.
Fig. 1 Case examples of CCTA with incorporation of FFRct and the ICA result. Case 1 presents the CCTA of a patient with non-obstructive disease in the LAD, as expected owing to the high sensitivity and negative predictive value of CCTA, subsequent ICA with FFR measurements confirmed non-significant CAD. The diagnostic performance of CCTA is, however, hampered by a relatively high rate of false-positive findings, an example is seen in Case 2. Incorporation of FFRct analysis in the assessment of CCTA can lead to a shift from false-positive results to true negatives (Case 2) and can confirm the significance of CAD as seen in Case 3. CAD coronary artery disease, CCTA coronary computed tomography angiography, DS diameter stenosis, FFR fractional flow reserve, FFRct CCTA derived FFR, ICA invasive coronary angiography, LAD left anterior descending artery which might go unnoticed on relative uptake images of PET and SPECT as these are dependent on normally perfused myocardium to serve as reference area (Fig. 3; [18, 19]). The optimal quantitative MBF cut-off to detect significant CAD has been studied by Danad and colleagues, who showed a hyperaemic MBF of ≤ 2.3 ml/min/g to be the optimal threshold to detect FFR-defined disease [20]. In addition to hyperaemic MBF, coronary flow reserve (CFR) can be calculated by dividing hyperaemic MBF by baseline MBF. CFR has a lower accuracy for detecting significant CAD as compared with hyperaemic MBF [20]. Dependency of CFR on both baseline and hyperaemic MBF probably contributes to this finding, as diminished CFR is not necessarily concomitant with reduced hyperaemic MBF but can be a result of high baseline values. Although CFR has been shown to be of incremental prognostic value it seems justified that for diagnostic purposes stress-only PET protocols suffice, obviating the need for baseline perfusion imaging leading to a reduction of radiation dose and scan acquisition time [21, 22]. Furthermore, as recently published, [15O]H2O PET derived hyperaemic MBF predicts adverse patient outcome independently of CFR in patients with suspected CAD [23].

Hybrid cardiac PET/CCTA imaging, more than the sum of its parts?

Interestingly, [15O]H2O PET can be performed on hybrid PET/CT scanners which allow assessment of coronary anatomy and functional significance of observed disease within one single scanning session [24]. In the Amsterdam University Medical Center (UMC), a clinical cohort of patients with suspected obstructive CAD underwent combined CCTA and
 favour of invasive approaches remains, as SPECT derived findings are reported to have a lower sensitivity but a higher specificity as compared with 

Although not yet used in clinical practice, PET serves as an attractive alternative with a number of advantages over SPECT, including the ability to perform a true hybrid approach when combining PET with CCTA. The PACIFIC trial utilised a hybrid approach with 18F-Flurpiridaz PET and CCTA, and demonstrated the incremental diagnostic value of combining PET with CCTA. The findings of the PACIFIC trial have been confirmed by prospective studies, such as the DAN-NICAD study, showing a low sensitivity of SPECT but a higher diagnostic accuracy of hybrid imaging.

CCTA derived plaque burden and morphology, more than meets the eye

As mentioned previously, CCTA allows for the assessment of obstructive CAD and in addition permits the visualisation and quantification of plaque burden and morphology. Adverse plaque characteristics such as positive remodelling, low attenuation plaque, and calcification are associated with the occurrence of acute coronary syndromes. Plaque burden and morphology harbours, beside prognostic value, information about the effect of atherosclerosis on downstream perfusion as assessed by PET. Driessen et al. showed that positive remodelling and non-calcified plaque volume have a detrimental effect on both hyperaemic and FFR independent of lesion severity, whereas spotty calcification and low attenuation plaque negatively affected FFR but not PET derived hyperaemic MBF. In contrast to FFR, the invasively obtained resting pressure index instantaneous wave-free ratio (iFR) showed not to be associated with high-risk plaque features.

Reversing the roles: invasively measured indices referenced by [15O]H2O PET determined MBF

As mentioned previously, [15O]H2O PET derived MBF is considered the reference standard for non-invasive assessment of quantitative myocardial perfusion. However, absolute coronary flow can also be invasively measured using continuous intracoronary infusion of saline, known as continuous thermodilution. Everaars et al. were the first to validate the invasive quantification of MBF by means of this thermodilution technique using [15O]H2O PET derived MBF as reference and demonstrated a near perfect correlation between the two indices. This novel technique is, however, not yet used in clinical practice in contrast to...
Case examples of $[^{15}O]$H$_2$O PET MPI and subsequent ICA. Case examples of results obtained through $[^{15}O]$H$_2$O PET MPI and subsequent ICA with FFR measurements. Case 1 demonstrates a patient with normal hyperaemic perfusion above the cut-off defining ischaemia in all vascular territories ($\leq 2.30$ ml/min/g). ICA in conjunction with FFR measurements confirmed the presence of non-significant CAD. A defect with diminished hyperaemic perfusion in the LAD territory is displayed in Case 2, the patient was referred for ICA which demonstrated a sub-total lesion of the proximal LAD with non-significant CAD of the RCA and Cx. Furthermore, quantitative PET MPI can be used to determine the presence of globally diminished perfusion, which can be due to multivessel CAD (Case 3) or possible microvascular disease (Case 4). CTO chronic coronary total occlusion, Cx circumflex artery, RCA right coronary artery, other abbreviations as in Figs. 1 and 2.
Table 1  Diagnostic performance of CCTA, SPECT, [15O]H2O PET, and hybrid imaging for diagnosing FFR-defined significant CAD as observed in the PACIFIC trial [27]. Adapted from and with permission of the American Medical Association

| Characteristics | CCTA | SPECT | PET | SPECT/CCTA | PET/CCTA |
|-----------------|------|-------|-----|------------|----------|
| **Per patient** |      |       |     |            |          |
| Sensitivity     | 90 (82–95) | 57 (46–67) | 87 (78–93) | 50 (39–61) | 74 (64–83) |
| Specificity     | 60 (51–69) | 94 (88–98) | 84 (75–89) | 97 (93–99) | 92 (86–96) |
| PPV             | 64 (55–73) | 88 (77–95) | 81 (72–89) | 94 (83–99) | 88 (79–94) |
| NPV             | 89 (80–95) | 73 (65–80) | 89 (81–94) | 71 (63–78) | 82 (74–88) |
| Accuracy        | 74 (67–79) | 77 (71–83) | 85 (80–90) | 76 (70–82) | 84 (79–89) |
| **Per vessel**  |      |       |     |            |          |
| Sensitivity     | 72 (64–79) | 39 (32–48) | 81 (73–87) | 35 (27–43) | 64 (55–71) |
| Specificity     | 78 (74–82) | 96 (94–98) | 75 (69–81) | 99 (98–100) | 97 (95–98) |
| PPV             | 52 (44–59) | 80 (70–87) | 59 (51–66) | 87 (65–96) | 87 (79–92) |
| NPV             | 87 (83–91) | 81 (76–85) | 92 (88–95) | 81 (76–85) | 88 (84–91) |
| Accuracy        | 77 (73–80) | 82 (78–85) | 79 (75–83) | 83 (79–86) | 88 (85–91) |

Table adapted from Danad et al. [27]

CCTA coronary computed tomography angiography, NPV negative predictive value, PET positron emission tomography, PPV positive predictive value, SPECT single-photon emission computed tomography.

Fig. 4 The association of CCTA derived plaque characteristics with impaired hyperaemic MBF measured by [15O]H2O PET and invasively measured FFR. Driessen et al. studied the effect of CT-derived plaque characteristics on hyperaemic MBF and FFR and demonstrated luminal stenosis severity to be the strongest predictor of impaired hyperaemic MBF and FFR. Positive remodelling and noncalcified plaque volume negatively influenced perfusion and FFR, whereas spotty calcification and low attenuation plaque affected FFR but not hyperaemic MBF. Figure adapted from Driessen et al. [12]. Adapted from and with permission of Elsevier. MBF myocardial blood flow, other abbreviations as in Figs. 1 and 2.

Do we need MPI in the future or can computational models do the job?

In recent years novel techniques have been developed that assess lesion-specific significance by estimating invasive FFR solely based on 3D models of the coronary vasculature and computational fluid dynamics. Advantages of these computational models are that they obviate the need to use pressure wires and invasive functional assessment of CAD during resting conditions [34].

routinely obtained pressure indices FFR, iFR and ratio of resting distal pressure (Pd) and aortic pressure (Pa) (Pd/Pa), which are all able to assess the functional significance of epicardial lesions [34]. Whereas FFR is measured during hyperaemic conditions, iFR and resting Pd/Pa are obtained without inducing hyperaemia. De Waard et al. investigated whether resting invasive pressure indices were capable of detecting impaired hyperaemic MBF as well as the invasive reference standard FFR, and demonstrated all pressure indices to have a similar diagnostic performance when referenced by [15O]H2O PET. This supports the
duce hyperaemia. One of these techniques is FFRct, which was highlighted previously, another is quantitative flow ratio (QFR) which is derived from ICA cine contrast images. FFRct and QFR demonstrate a similar and high diagnostic accuracy when referenced by FFR [3, 35]. In the PACIFIC population, QFR had a higher accuracy compared with SPECT and PET MPI for the diagnosis of lesion-specific ischaemia [36]. Noteworthy, QFR computation was not feasible in 48% of the vessels due to the lack of a predefined dedicated QFR acquisition protocol in the PACIFIC trial hampering a per-patient analysis. Introduction of these computational-based techniques in the clinical arena will delineate their role in the diagnostic armamentarium.

\[^{15}O\]H\textsubscript{2}O PET MPI in patients with chronic coronary total occlusion

Clinical guidelines emphasise the importance of ischaemia and viability assessment in patients with a chronic coronary total occlusion (CTO) prior to revascularisation due to the slightly increased risk of procedural complications as compared with revascularisation of non-CTO lesions and furthermore to establish an appropriate indication [37]. In the dedicated CTO program of the Amsterdam UMC, \[^{15}O\]H\textsubscript{2}O PET MPI is used to assess the presence and extent of ischaemia in patients with a potential indication for percutaneous coronary intervention (PCI) of a CTO. Prior reports from this program demonstrated marked ischaemia (>10% of the left ventricle) to be present in practically all patients with a CTO irrespective of collateral status [38, 39]. In fact, the median extent of ischaemia related to the CTO lesion was 24% of the left ventricle [39]. Of note, all patients had an indication for evaluation of the CTO with the majority of patients (>80%) being symptomatic. Furthermore, the extent and depth of ischaemia was observed to be more profound in patients with a CTO as compared with patients with severe haemodynamically significant lesions as determined by FFR (mean FFR: 0.55 ± 0.19) [10, 40]. These findings may be expected given the absence of antegrade flow and the complete dependence of myocardium subtended by a CTO on collateral supply. However, in clinical practice it is regularly assumed that well-developed collaterals preclude stress-induced ischaemia. This assumption may be refuted and should not be used as a reason to defer a patient from revascularisation.

\[^{15}O\]H\textsubscript{2}O PET MPI to evaluate effects of CTO PCI

Patients treated successfully by CTO PCI in the Amsterdam UMC were prospectively rescheduled for \[^{15}O\]H\textsubscript{2}O PET MPI 3 months after revascularisation to evaluate the effects on myocardial perfusion. Stuijifzand et al. demonstrated that CTO PCI resulted in large reductions of the perfusion defect size accompanied by significant increases in hyperaemic MBF (Fig. 5; [38]). The median decrease in defect size after CTO PCI was reported to be three segments which equals 17.5% of left ventricular myocardium according to the standardised 17-segment model and can be considered a substantial reduction in ischaemic burden [39, 41]. In addition, successful CTO PCI improved myocardial perfusion to a similar extent as successful PCI of haemodynamically significant non-occlusive lesions in a subgroup of patients from the PACIFIC trial [10, 39, 41]. These results indicate that the expected benefit of CTO PCI, if successfully and safely performed by experienced hands, should not be considered inferior to non-CTO PCI if (silent) ischaemia reduction is the indication for revascularisation. Of note, microvascular (dys)function has an important impact on the ability to restore perfusion. Several risk factors for microvascular dysfunction (left ventricular dysfunction, a history of myocardial infarction in the CTO territory) are negative predictors (Fig. 5; [38]).
of improvement in hyperaemic MBF [42]. In contrast, if hyperaemic MBF is higher in surrounding myocardium not subtended by obstructive CAD (indicating normal functioning microvasculature), the gain in hyperaemic MBF in the CTO area that can be expected after PCI is higher as well [42].

Conclusion
Coronary CTA and MPI are established non-invasive imaging modalities to diagnose CAD with technique-dependent advantages such as the high negative predictive value of CCTA and the ability of MPI to assess the functional severity of CAD. Computational fluid-based techniques such as FFRct and QFR diversify the diagnostic opportunities available to the physician. Although novel insights and developments in the field of (non)invasive imaging are promising and might lead to a more judicious assessment of CAD, the incremental value of imaging-based treatment strategies to improve patient outcome should be carefully reviewed.

Conflict of interest PA. van Diemen, S.P. Schumacher, R.S. Driessen, M.J. Bom, W.J. Stuijfzand, H. Everaars, R.W. de Winter, P.G. Raijmakers, A.C. van Rossum, A. Hirsch and I. Danad have reported that they have no relationships relevant to the contents of this paper to disclose. P. Knaapen has received research grants from HeartFlow.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References
1. Back M, Yurdagul A, Tabas I, et al. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol. 2019;16:389–406.
2. Knutti J, Wijns W, Saraste A, et al. ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2019;2020(41):407–77.
3. Danad I, Szymonifka J, Twisk JR, et al. Diagnostic performance of cardiac imaging methods to diagnose ischaemia-causing coronary artery disease when directly compared with fractional flow reserve as a reference standard: a meta-analysis. Eur Heart J. 2017;38:991–8.
4. Kalisz K, Buethe J, Saboo SS, et al. Artifacts at Cardiac CT: Physics and Solutions. Radiographics. 2016;36:2064–83.
5. Douglas PS, Hoffmann U, Patel MR, et al. Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med. 2015;372:1291–300.
6. Investigators S-H, Newby DE, Adamson PD, et al. Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. N Engl J Med. 2018;379:924–33.
7. Min JK, Taylor CA, Achenbach S, et al. Noninvasive Fractional Flow Reserve Derived From Coronary CT Angiography: Clinical Data and Scientific Principles. JACC Cardiovasc Imaging. 2015;8:1209–22.
8. Min JK, Leipsic J, Pencina MJ, et al. Diagnostic accuracy of fractional flow reserve from anatomic CT angiography. JAMA. 2012;308:1237–45.
9. Norgaard BL, Leipsic J, Gaur S, et al. Diagnostic Performance of Noninvasive Fractional Flow Reserve Derived From Coronary Computed Tomography Angiography in Suspected Coronary Artery Disease The NXT Trial. Analysis of Coronary Blood Flow Using CT Angiography: Next Steps. J Am Coll Cardiol. 2014;63:1145–55.
10. Driessen RS, Danad I, Stuijfzand WJ, et al. Comparison of Coronary Computed Tomography Angiography, Fractional Flow Reserve, and Perfusion Imaging for Ischemia Diagnosis. J Am Coll Cardiol. 2019;73:161–73.
11. Douglas PS, De Bruyne B, Pontone G, et al. 1-Year Outcomes of FFRCT-Guided Care in Patients With Suspected Coronary Disease The PLATFORM Study. J Am Coll Cardiol. 2016;68:435–45.
12. Driessen RS, Stuijfzand WJ, Rajmakers PG, et al. Effect of Plaque Burden and Morphology on Myocardial Blood Flow and Fractional Flow Reserve. J Am Coll Cardiol. 2018;71:499–509.
13. Gaur S, Overhus KA, Dey D, et al. Coronary plaque quantification and fractional flow reserve by coronary computed tomography angiography identify ischaemia-causing lesions. Eur Heart J. 2016;37:1220–7.
14. Park HB, Heo R, Hartaigh BO, et al. Atherosclerotic Plaque Characteristics by CT Angiography Identify Coronary Lesions That Cause Ischemia. JACC Cardiovasc Imaging. 2015;8:1–10.
15. Hampe N, Wolterink JM, van Velzen SG, et al. Machine learning for assessment of coronary artery disease in cardiac CT: a survey. Front Cardiovasc Med. 2019;6:172.
16. Driessen RS, Rajmakers PG, Stuijfzand WJ, et al. Myocardial perfusion imaging with PET. Int J Cardiovasc Imaging. 2017;33:1021–31.
17. Knaapen P, de Haan S, Hoekstra OS, et al. Cardiac PET-CT: advanced hybrid imaging for the detection of coronary artery disease. Neth Heart J. 2010;18:90–8.
18. Berman DS, Kang X, Slomka P, et al. Underestimation of extent of ischemia by gated SPECT myocardial perfusion imaging in patients with left main coronary artery disease. J Nucl Cardiol. 2007;14:521–8.
19. Lima RS, Watson DD, Goode AR, et al. Incremental value of combined perfusion and function over perfusion alone by gated SPECT myocardial perfusion imaging for detection of severe three-vessel coronary artery disease. J Am Coll Cardiol. 2003;42:64–70.
20. Danad I, Uusitalo V, Kero T, et al. Quantitative assessment of myocardial perfusion in the detection of significant coronary artery disease: cutoff values and diagnostic accuracy of quantitative [(15)O]H2O PET imaging. J Am Coll Cardiol. 2014;64:1464–75.
21. Herzog BA, Husmann L, Valenta I, et al. Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. J Am Coll Cardiol. 2009;54:150–6.
22. Patel KK, Spertus JA, Chan PS, et al. Myocardial blood flow reserve assessed by positron emission tomography myocardial perfusion imaging identifies patients with a sur-
vival benefit from early revascularization. Eur Heart J. 2020;41:759–68.
23. BomMJ, van Diemen PA, Driessen RS, et al. Prognostic value of [15O]H2O positron emission tomography-derived global and regional myocardial perfusion. Eur Heart J Cardiovas Imaging. 2020;21(7):777–86
24. Danad I, Raijmakers PG, Knaapen P. Diagnosing coronary artery disease with hybrid PET/CT: It takes two to tango. J Nucl Cardiol. 2013;20:874–90.
25. Danad I, Raijmakers PG, Appelman YE, et al. Hybrid Imaging Using Quantitative (H2O)-O-15 PET and CT-Based Coronary Angiography for the Detection of Coronary Artery Disease. J Nucl Med. 2013;54:55–63.
26. Danad I, Raijmakers PG, Harms HJ, et al. Effect of cardiac hybrid O-15-water PET/CT imaging on downstream referral for invasive coronary angiography and revascularization rate. Eur Heart J Card Img. 2014;15:170–9.
27. Danad I, Raijmakers PG, Driessen RS, et al. Comparison of Coronary CT Angiography, SPECT, PET, and Hybrid Imaging for Diagnosis of Ischemic Heart Disease Determined by Fractional Flow Reserve. JAMA Cardiol. 2017;2:1100–7.
28. de Jong MC, Genders TSS, van Geuns RJ, et al. Diagnostic performance of stress myocardial perfusion imaging for coronary artery disease: a systematic review and meta-analysis. Eur Radiol. 2012;22:1881–95.
29. Nissen L, Winther S, Westra J, et al. Adverse plaque characteristics relate more strongly with hyperemic fractional flow reserve than with resting instantaneous wave-free ratio. JACC Cardiovasc Imaging. 2020;13(3):746–56.
30. Puchner SB, Liu T, Mayrhofer T, et al. Continuous thermodilution to assess absolute flow and microvascular resistance: validation in humans using [15O]H2O positron emission tomography. Eur Heart J. 2019;40:2350–9.
31. Schumacher SP, Liu T, Mayrhofer T, et al. Prognostic value of [15O]H2O positron emission tomography myocardial perfusion imaging: a PACIFIC trial sub-study. Eur Heart J. 2018;39:4072–81.
32. Schumacher SP, Kockx M, Stuijfzand WJ, et al. Relationship between Extent of Ischaemic Burden and Changes in Absolute Myocardial Perfusion after Chronic Total Occlusion Percutaneous Coronary Intervention. Eur Heart J. 2017;38:345–54.
33. Schumacher SP, Kocks M, Stuijfzand WJ, et al. Recovery of myocardial perfusion after percutaneous coronary intervention of chronic total occlusions on myocardial perfusion and left ventricular function. EuroIntervention. 2017;13:345–54.
34. de Waard GA, Danad I, Petraco R, et al. Fractional flow reserve, instantaneous wave-free ratio, and resting Pd/Pa compared with [15O]H2O positron emission tomography myocardial perfusion imaging: a PACIFIC trial sub-study. Eur Heart J. 2018;39:4072–81.
35. Westra J, Tu S, Campo G, et al. Diagnostic performance of quantitative flow ratio in prospectively enrolled patients: An individual patient-data meta-analysis. Catheter Cardiovasc Interv. 2019;94:693–701.
36. van Diemen PA, Driessen RS, Kooistra RA, et al. Comparison Between the Performance of Quantitative Flow Ratio and Perfusion Imaging for Diagnosing Myocardial Ischemia. JACC Cardiovasc Imaging. 2020. https://doi.org/10.1016/j.jcmg.2020.02.012.
37. Schumacher SR, Stuijfzand WJ, Opolski MP, et al. Percutaneous Coronary Intervention of Chronic Total Occlusions: When and How to Treat. Cardiovasc Revasc Med. 2019;20:513–22.
38. Stuijfzand WJ, Biesbroek PS, Raijmakers PG, et al. Effects of successful percutaneous coronary intervention of chronic total occlusions on myocardial perfusion and left ventricular function. EuroIntervention. 2017;13:345–54.
39. Schumacher SR, van Geuns RJ, Driessen RS, et al. Imaging Using Quantitative (H2O)-O-15 PET and CT-Based Coronary Angiography: A Comparison With Fractional Flow Reserve, Instantaneous Wave-Free Ratio, and Resting Pd/Pa Compared With [15O]H2O Positron Emission Tomography Myocardial Perfusion Imaging: A PACIFIC Trial Sub-Study. Eur Heart J. 2018;39:4072–81.
40. Schumacher SR, Driessen RS, Stuijfzand WJ, et al. Recovery of myocardial perfusion after percutaneous coronary intervention of chronic total occlusions is comparable to hemo-dynamically significant non-occlusive lesions. Catheter Cardiovasc Interv. 2019;93:1059–66.
41. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart—A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105:539–42.
42. Schumacher SR, Stuijfzand WJ, Driessen RS, et al. Impact of Specific Crossing Techniques in Chronic Total Occlusion Percutaneous Coronary Intervention on Recovery of Absolute Myocardial Perfusion. Circ Cardiovasc Interv. 2019;12(11):e00684.
43. Driessen RS, Danad I, Stuijfzand WJ, et al. Fractional Flow Reserve Imaging: A Comparison With Fractional Flow. Reserv Circ Cardiovasc Imaging. 2018;11(5):e007417.